Stock Christopher, Shum Jason H
George E. Wahlen Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT 84148, USA.
J Pain Palliat Care Pharmacother. 2004;18(3):35-54.
The federal Drug Abuse Treatment Act 2000 (DATA) opened a window of opportunity for patients with the disease of addiction by providing increased access to options for treatment. Previously, only methadone maintenance, approved for use only through specially regulated clinics, was available to treat opioid addiction. DATA allows any physician choosing to take a short specialty training course and become certified to prescribe buprenorphine. Buprenorphine and buprenorphine/ naloxone (Subutex, Suboxone) can be prescribed by certified physicians in a traditional office setting to treat patients with opioid dependence. Clinical studies indicate buprenorphine maintenance is as effective as methadone maintenance in retaining patients in substance abuse treatment and reducing illicit opioid use. Sublingual buprenorphine is more effective than clonidine or clonidine/naltrexone in short-term opioid detoxification treatment. Buprenorphine provides an additional tool to treat opioid addiction and improve the quality of lives of these patients. More physicians are needed to treat patients with addiction. DATA facilitates this by removing existing barriers and increasing access to treatment.
2000年联邦《药物滥用治疗法案》(DATA)为成瘾患者打开了一扇机会之窗,增加了治疗选择。此前,只有美沙酮维持治疗(仅通过特殊监管的诊所批准使用)可用于治疗阿片类药物成瘾。DATA允许任何选择参加短期专业培训课程并获得认证的医生开具丁丙诺啡。经认证的医生可以在传统办公室环境中开具丁丙诺啡和丁丙诺啡/纳洛酮(舒倍生、舒泊西)来治疗阿片类药物依赖患者。临床研究表明,丁丙诺啡维持治疗在使患者继续接受药物滥用治疗和减少非法阿片类药物使用方面与美沙酮维持治疗效果相当。在短期阿片类药物脱毒治疗中,舌下含服丁丙诺啡比可乐定或可乐定/纳曲酮更有效。丁丙诺啡为治疗阿片类药物成瘾和改善这些患者的生活质量提供了一种额外的工具。需要更多医生来治疗成瘾患者。DATA通过消除现有障碍和增加治疗途径来推动这一进程。